IDE574 + Fulvestrant for Breast Cancer

This trial tests a new treatment called IDE574 for certain advanced or metastatic cancers. The study aims to determine if IDE574 is safe and effective, both alone and with fulvestrant, specifically for ER+ HER2- breast cancer. It seeks participants who have tried other treatments without success, particularly those whose breast cancer progressed after hormone therapy and CDK4/6 inhibitors. This trial may suit individuals managing advanced breast cancer and considering new treatment options. As a Phase 1, Phase 2 trial, it focuses on understanding how the treatment works in people and measuring its effectiveness in an initial group.

The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Research has shown that IDE574 has been effective in fighting tumors in earlier studies. It targets enzymes involved in cancer growth and successfully lowers tumor markers in various cancer models. However, detailed safety information is not yet available, so its safety for humans remains uncertain.

Researchers are further testing IDE574 in combination with fulvestrant. Fulvestrant is a well-known breast cancer treatment and is generally well-tolerated, though some individuals may experience fatigue or nausea.

Researchers are excited about IDE574 for breast cancer because it offers a new approach to treatment. Unlike current treatments that often target estrogen receptors or HER2 proteins, IDE574 works by a different mechanism, potentially providing a new option for patients with ER+ HER2- advanced or metastatic breast cancer. This treatment is being tested both alone and in combination with fulvestrant, which is known for blocking estrogen receptors. The combination might enhance effectiveness, offering hope for improved outcomes compared to existing therapies like hormone blockers or chemotherapy.

Research has shown that IDE574, a new drug, has delivered promising results in early tests against certain solid tumors, including breast cancer. It blocks specific enzymes, KAT6 and KAT7, which helps stop tumor growth. In this trial, some participants will receive IDE574 alone, while others will receive it in combination with fulvestrant, a current treatment. Combining IDE574 with fulvestrant may lead to better outcomes. Previous studies with similar drug combinations have demonstrated that patients can live longer without their disease worsening. Although clinical data collection is ongoing, IDE574 could become a promising new option for treating advanced breast cancer.⁴⁶⁷⁸⁹